Literature DB >> 1319088

Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

P Collard1, P Weynants, C Francis, D O Rodenstein.   

Abstract

BACKGROUND: Relapse of small cell lung cancer is not usually treated with further chemotherapy as results are considered to be disappointing. METHODS AND
RESULTS: Six patients with relapse of small cell lung cancer after a complete initial response and remission of more than one year responded to repeat treatment with the initial chemotherapy comprising carboplatin, etoposide, and epirubicin. The second remission ranged from six months to more than 15 months.
CONCLUSION: In patients with a relapse of small cell lung cancer after a complete initial response and prolonged remission retreatment with the initial combination chemotherapy cannot be dismissed and requires further study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319088      PMCID: PMC463753          DOI: 10.1136/thx.47.5.369

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  Small cell lung cancer.

Authors:  G Crompton
Journal:  BMJ       Date:  1990-01-27

Review 2.  Duration of chemotherapy in small cell lung cancer.

Authors:  S G Spiro; R L Souhami
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

3.  Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.

Authors:  P E Postmus; H H Berendsen; N van Zandwijk; T A Splinter; J T Burghouts; W Bakker
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

4.  Small-cell carcinoma of lung: reinduction therapy after late relapse.

Authors:  G Batist; D C Ihde; A Zabell; A S Lichter; S R Veach; M H Cohen; D N Carney; P A Bunn
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

5.  Unmaintained remissions in multiple myeloma.

Authors:  R Alexanian; E Gehan; A Haut; J Saiki; J Weick
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

6.  Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.

Authors:  A U Buzdar; S S Legha; G N Hortobagyi; H Y Yap; C L Wiseman; A Distefano; F C Schell; B C Barnes; L T Campos; G R Blumenschein
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

7.  Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.

Authors:  V Seltzer; S Vogl; B Kaplan
Journal:  Gynecol Oncol       Date:  1985-06       Impact factor: 5.482

8.  Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy.

Authors:  A G Wendt; S E Jones; S E Salmon
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

9.  Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.

Authors:  S G Spiro; R L Souhami; D M Geddes; C M Ash; H Quinn; P G Harper; J S Tobias; M Partridge; D Eraut
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

10.  Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial.

Authors:  M J Byrne; G van Hazel; J Trotter; F Cameron; J Shepherd; B Cassidy; V Gebski
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more
  1 in total

Review 1.  Current concepts in the management of small cell lung cancer.

Authors:  Apar Kishor Ganti; William W West; Weining Zhen
Journal:  Indian J Med Res       Date:  2013-06       Impact factor: 2.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.